Skip to main
AGEN
AGEN logo

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Agenus Inc. presents a positive outlook due to its diverse pipeline of therapies aimed at activating the immune system, which includes antibody candidates botensilimab and balstilimab. The company's focus on compassionate use programs provides an additional revenue stream while generating real-world clinical evidence, particularly highlighted by promising efficacy in treating triple-negative and ER+ breast cancer through the NEOASIS trial. Furthermore, early favorable regulatory sentiment regarding bot/bal in metastatic colorectal cancer (MSS-CRC) suggests potential for additional growth and development opportunities in the near future.

Bears say

Agenus Inc's financial outlook is marred by several significant risks including the potential for emerging safety signals in its clinical or preclinical programs, which could negatively impact investor confidence. Moreover, there are concerns regarding the efficacy of its clinical programs potentially falling short of expectations, compounded by the possibility of increased competition from existing and emerging therapies in the market. Additionally, the company faces challenges related to regulatory approvals, ongoing financing requirements, and the need to secure robust intellectual property protection, all of which may hinder its growth prospects and overall market performance.

Agenus (AGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Agenus (AGEN) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.